Your browser doesn't support javascript.
loading
Emergency contraception for individuals weighing 80 kg or greater: A randomized trial of 30 mg ulipristal acetate and 1.5 mg or 3.0 mg levonorgestrel.
Edelman, Alison; Jensen, Jeffrey T; Brown, Jill; Thomas, Michael; Archer, David F; Schreiber, Courtney A; Teal, Stephanie; Westhoff, Carolyn; Dart, Clint; Blithe, Diana L.
Afiliação
  • Edelman A; Department of OB/GYN, Oregon Health & Science University, Portland, OR, United States. Electronic address: edelmana@ohsu.edu.
  • Jensen JT; Department of OB/GYN, Oregon Health & Science University, Portland, OR, United States.
  • Brown J; Department of OB/GYN, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
  • Thomas M; Department of OB/GYN, University of Cincinnati, Cincinnati, OH, United States.
  • Archer DF; Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA, United States.
  • Schreiber CA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
  • Teal S; Department of OB/GYN, University Hospitals, Cleveland, OH, United States.
  • Westhoff C; Department of OB/GYN, Columbia University, New York, NY, United States.
  • Dart C; Health Decisions, A division of Premier Research, Durham, NC, United States.
  • Blithe DL; Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, United States.
Contraception ; 137: 110474, 2024 Sep.
Article em En | MEDLINE | ID: mdl-38663539
ABSTRACT

OBJECTIVES:

To compare the efficacy of emergency contraception (EC) regimens used within 72 hours of unprotected intercourse in individuals weighing ≥80 kg. STUDY

DESIGN:

We enrolled reproductive-aged healthy women in a multicenter, single-blind, randomized study of levonorgestrel 1.5 mg (LNG1X) and 3.0 mg (LNG2X) and ulipristal acetate 30 mg (UPA) (enrollment goal 1200). Key eligibility requirements included regular cycles, weight >/= 80kg, unprotected intercourse within 72 hours, no recent use of hormonal contraception, a negative urine pregnancy test (UPT), and willingness to abstain from intercourse until next menses. To assess our primary outcome of incidence of pregnancy, participants completed home UPTs; if no menses by 2-weeks post-treatment, or a positive UPT, they returned for an in-person visit with quantitative serum human chorionic gonadotropin and ultrasound.

RESULTS:

We enrolled and randomized 532; 44 were not dosed or not evaluable for primary end point, leaving an analyzable sample of 488 (173 LNG1X, 158 LNG2X, 157 UPA) with similar demographics between groups (mean age 29.6 years [5.74], body mass index 37.09 kg/m2 [6.95]). Five pregnancies occurred (LNG1X n = 1, LNG2X n = 1, UPA n = 3); none occurred during the highest at-risk window (day of ovulation and the 3 days prior). We closed the study before achieving our enrollment goal because the low pregnancy rate in all groups established futility based on an interim blinded analysis.

CONCLUSIONS:

Although slow enrollment limited our study power, we found no differences in pregnancy rates between EC regimens among women weighing 80 kg or more. Our results are not able to refute or support differences between the treatment arms. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, www.clincialtrials.gov Clinical trials# NCT03537768. IMPLICATIONS Women weighing 80 kg or more experienced no differences in pregnancy rates between oral EC regimens but due to several significant study limitations including sample size and the lack of a study population at high risk of pregnancy, our results are not able to determine if differences in treatment effectiveness exist.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Levanogestrel / Anticoncepção Pós-Coito / Norpregnadienos Limite: Adolescent / Adult / Female / Humans / Pregnancy Idioma: En Revista: Contraception Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Levanogestrel / Anticoncepção Pós-Coito / Norpregnadienos Limite: Adolescent / Adult / Female / Humans / Pregnancy Idioma: En Revista: Contraception Ano de publicação: 2024 Tipo de documento: Article